Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current Cancer Drug Targets

• Publication date

  2011-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/156800911794519752PMID 21247388PMCID PMC3306611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Marine Antitumor Drugs: Status, Shortfalls and Strategies

  2010cited by this paper
• Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

  2010cited by this paper
• Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs.

  2010cited by this paper
• Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides

  2010cited by this paper
• A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

  2010cited by this paper
• The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.

  2010cited by this paper
• Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model

  2010cited by this paper
• Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target

  2010cited by this paper
• Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

  2010cited by this paper
• Fluorocurcumins as Cyclooxygenase-2 Inhibitor: Molecular Docking, Pharmacokinetics and Tissue Distribution in Mice

  2009cited by this paper
• New Difluoro Knoevenagel Condensates of Curcumin, Their Schiff Bases and Copper Complexes as Proteasome Inhibitors and Apoptosis Inducers in Cancer Cells

  2009cited by this paper
• Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.

  2009cited by this paper
• High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

  2009cited by this paper
• Bortezomib: a review of its use in patients with multiple myeloma.

  2009cited by this paper
• An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

  2009cited by this paper
• Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

  2009cited by this paper
• Clinical development of novel proteasome inhibitors for cancer treatment

  2009cited by this paper
• Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

  2009cited by this paper
• Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

  2009cited by this paper
• Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

  2009cited by this paper
• Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.

  2009cited by this paper
• Ascorbic acid inhibits antitumor activity of bortezomib in vivo

  2009cited by this paper
• A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

  2009cited by this paper
• Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)

  2009cited by this paper
• Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

  2009cited by this paper
• Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction

  2009cited by this paper
• Tea polyphenols, their biological effects and potential molecular targets.

  2008cited by this paper
• Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

  2008cited by this paper
• Bortezomib in mantle cell lymphoma.

  2008cited by this paper
• Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.

  2008cited by this paper
• Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.

  2008cited by this paper
• Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.

  2008cited by this paper
• The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

  2008cited by this paper
• Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.

  2008cited by this paper
• Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

  2008cited by this paper
• Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.

  2008cited by this paper
• Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

  2008cited by this paper
• Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway

  2008cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

  2008cited by this paper
• Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

  2008cited by this paper
• Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

  2007cited by this paper
• Bortezomib for the Treatment of Mantle Cell Lymphoma

  2007cited by this paper
• Constitutive/Hypoxic Degradation of HIF-α Proteins by the Proteasome Is Independent of von Hippel Lindau Protein Ubiquitylation and the Transactivation Activity of the Protein*

  2007cited by this paper
• A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

  2007cited by this paper
• A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors

  2007cited by this paper
• Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

  2007cited by this paper
• Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts

  2007cited by this paper
• Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition

  2007influential reference
• The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

  2007cited by this paper
• Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.

  2007cited by this paper
• Bortezomib disrupts tumour–dendritic cell interactions in myeloma and lymphoma: therapeutic implications

  2007cited by this paper
• A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience

  2007cited by this paper
• A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.

  2007cited by this paper
• A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.

  2007cited by this paper
• Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer

  2007cited by this paper
• Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.

  2006cited by this paper
• Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

  2006cited by this paper
• Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

  2006cited by this paper
• The proteasome as a potential target for novel anticancer drugs and chemosensitizers.

  2006cited by this paper
• Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.

  2006cited by this paper
• A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

  2006cited by this paper
• A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

  2006cited by this paper
• Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

  2006cited by this paper
• Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies

  2006cited by this paper
• Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.

  2006cited by this paper
• Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.

  2006cited by this paper
• Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress

  2006cited by this paper
• Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

  2006cited by this paper
• The proteasome: a novel target for anticancer therapy

  2006cited by this paper
• Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

  2006cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• A novel proteasome inhibitor NPI-0052 as an anticancer therapy

  2006cited by this paper
• The ubiquitin-proteasome system

  2006cited by this paper
• United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

  2006cited by this paper
• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2005cited by this paper
• A phase II study of bortezomib in the treatment of metastatic malignant melanoma

  2005cited by this paper
• Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

  2005cited by this paper
• The ubiquitin proteasome pathway from bench to bedside.

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005cited by this paper
• The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.

  2005cited by this paper
• Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.

  2005cited by this paper
• Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

  2005cited by this paper
• Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.

  2005influential reference
• Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005influential reference
• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2005cited by this paper
• Ubiquitin signalling in the NF-κB pathway

  2005cited by this paper
• PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

  2005cited by this paper
• Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

  2005cited by this paper
• Ubiquitin signalling in the NF-kappaB pathway.

  2005cited by this paper
• Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.

  2005cited by this paper
• Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells

  2004cited by this paper
• Ubiquitin-proteasome system

  2004cited by this paper
• Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells.

  2004cited by this paper
• The development of proteasome inhibitors as anticancer drugs.

  2004cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

  2004cited by this paper
• Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors

  2004cited by this paper
• Inhibition of Proteasomal Function by Curcumin Induces Apoptosis through Mitochondrial Pathway*

  2004cited by this paper

• Unnatural amino acid-based miniPROTACs enable efficient oncoprotein degradation

  2026cites this paper
• Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein Degradation.

  2026cites this paper
• Comparative Investigation of Cytotoxic Effects of Structurally Diverse Small Molecules and In Silico Analysis of 1‐Acetyl‐4‐(4‐Hydroxyphenyl)piperazine

  2026cites this paper
• Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection.

  2026cites this paper
• Covalent chemistry in targeted protein degradation.

  2026cites this paper
• Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.

  2026cites this paper
• Drug Discovery and Repurposing for Coccidioides: A Systematic Review

  2025cites this paper
• Recent advances in the synthesis, reactivity, and applications of symmetrical and asymmetrical cross-conjugated dienones

  2025cites this paper
• Influence of PSMB6 and PSMB9 Genetic Polymorphisms on Bortezomib-Based Therapy Response in Newly Diagnosed Multiple Myeloma

  2025cites this paper
• The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy.

  2025cites this paper
• Bortezomib suppresses TGF-β1-mediated LOXL4 reduction through the inhibition of MEK/ERK pathways in MDA-MB-231 cells

  2025cites this paper
• Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically-diverse Caenorhabditis nematodes

  2025cites this paper
• Exploring the inhibition potential of 2,4,6-trifluorophenylboronic acid on horseradish peroxidase

  2025cites this paper
• Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor

  2025cites this paper
• Exploration of genes related to the development of cancer of unknown primary

  2025cites this paper
• In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?

  2025cites this paper
• Oleanolic Acid Amide Derivatives as 20s Proteasome Stimulators

  2025cites this paper
• Label-free protein-structure-sensitive live-cell microscopy for patient-specific assessment of myeloma therapy

  2025cites this paper
• PSMB10 maintains the stemness of chemotherapeutic drug-resistant leukemia cells by inhibiting senescence and cytotoxic T lymphocyte-mediated killing in a ubiquitinated degradation manner

  2025cites this paper
• Cancer Drug Bortezomib, a Proteasomal Inhibitor, Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress

  2025cites this paper
• Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial

  2025cites this paper
• Exploring the role of boron-containing compounds in biological systems: Potential applications and key challenges.

  2025cites this paper
• Targeting the Ubiquitin–Proteasome System for Cancer

  2025cites this paper
• Peptide-Mediated Modulation of miRNAs: A Novel Therapeutic Strategy for Cancer

  2025cites this paper
• Current landscape of the immunoproteasome: implications for disease and therapy

  2025cites this paper
• Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma

  2025cites this paper
• Ubiquitination dynamics in human tumour viruses: Viral infection, oncogenesis and antiviral therapy

  2025cites this paper
• Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma.

  2025cites this paper
• Cortical organoid-derived models of the melanoma brain metastatic niche enable prioritization of cancer-targeting drugs

  2025cites this paper
• Non-enzymatic protein targeting agents as a promising strategy for cancer treatment

  2025cites this paper
• The Hidden Hand of Endoplasmic Reticulum Stress in Anticancer Drug Resistance.

  2025cites this paper
• Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically diverse Caenorhabditis nematodes

  2025cites this paper
• Nanobubble-Enhanced Oral Delivery of Bortezomib: Optimizing Preparation and Characterization through Design of Experiment (DOE)

  2025cites this paper
• Targeting the ubiquitin-proteasome pathway in systemic lupus erythematosus

  2025cites this paper
• Genetic perturbation of cellular homeostasis regulates integrated stress response signaling to control Drosophila hematopoiesis

  2025cites this paper
• Transcription Factors and Methods for the Pharmacological Correction of Their Activity

  2025cites this paper
• Design and Synthesis of Potent Ridaifen Analogues: Evaluation as Anticancer, 20S Proteasomal Inhibitors, and Antiebola Virus Agents through In vitro and In Silico Studies

  2025cites this paper
• Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder

  2025cites this paper
• Radiosensitizers in Cancer Therapy: A Global Bibliometric Analysis

  2025cites this paper
• Immunotargets and Therapy for Systemic Lupus Erythematosus

  2025cites this paper
• Enhancing schistosomiasis drug discovery approaches with optimized proteasome substrates

  2025cites this paper
• Potential of histone deacetylase 6 inhibitors in alleviating chemotherapy-induced peripheral neuropathy

  2025cites this paper
• Enhanced Precision Therapy of Multiple Myeloma through Engineered Biomimetic Nanoparticles with Dual Targeting

  2024cites this paper
• Targeting Ubiquitin-Proteasome System (UPS) in Treating Osteoarthritis.

  2024cites this paper
• CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo

  2024cites this paper
• Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis

  2024cites this paper
• USP37 promotes diffuse large B-cell lymphoma progression by deubiquitinating and stabilizing c-myc

  2024cites this paper
• Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells

  2024influential citation
• Azobenzene-Tagged Photopeptides Exhibiting Excellent Selectivity and Light-Induced Cytotoxicity in MCF-7 Cells over HeLa and A549.

  2024cites this paper
• Fluorescent Sensing for Boronic acid derivatives: Design, Synthesis, Mechanism, Application and perspective in Boron Neutron Capture Therapy (BNCT)

  2024cites this paper
• The proteasome as a drug target for treatment of parasitic diseases.

  2024cites this paper
• Uncommon Presentation of Multiple Myeloma: Pleural Effusion and Extensive Extramedullary Involvement

  2024cites this paper
• Optimizing Niclosamide for Cancer Therapy: Improving Bioavailability via Structural Modification and Nanotechnology

  2024cites this paper
• Recent pharmacological insights on abating toxic protein species burden in neurological disorders: Emphasis on 26S proteasome activation.

  2024cites this paper
• Bortezomib-loaded immunoliposomes against CD44 expressing macrophages: an interplay for inflammation resolution.

  2024cites this paper
• Auxin-dependent post-translational regulation of MONOPTEROS in the Arabidopsis root.

  2024cites this paper
• Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders

  2024cites this paper
• gp78-regulated KAP1 phosphorylation induces radioresistance in breast cancer by facilitating PPP1CC/PPP2CA ubiquitination

  2024cites this paper
• Phenylboronic acid-functionalized biomaterials for improved cancer immunotherapy via sialic acid targeting.

  2024cites this paper
• Bortezomib-encapsulated metal–phenolic nanoparticles for intracellular drug delivery

  2024cites this paper
• Clickable Probes for Pathogen Proteasomes: Synthesis and Applications

  2024cites this paper
• The tumor microenvironment: shaping cancer progression and treatment response

  2024cites this paper
• Integrated proteasomal and lysosomal activity shape mTOR-regulated proteome remodeling

  2024cites this paper
• Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

  2024cites this paper
• Discovery of N-Benzylpiperidinol derivatives as USP7 inhibitors against Hematology.

  2024cites this paper
• Deciphering ER stress-unfolded protein response relationship by visualizing unfolded proteins in the ER.

  2024cites this paper
• Genetic risk factors for bortezomib-induced neuropathic pain in an Asian population: A genome-wide association study in South Korea.

  2024cites this paper
• Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor

  2024cites this paper
• Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989

  2024cites this paper
• Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation

  2024cites this paper
• Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

  2024cites this paper
• Exploring Ubiquitin-specific proteases as therapeutic targets in Glioblastoma.

  2024cites this paper
• Recent advances in targeted drug delivery systems for multiple myeloma.

  2024cites this paper
• TRAIL receptors as prognostic markers and survival predictors in ovarian cancer: A systematic review of clinical studies and meta-analysis

  2024cites this paper
• The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology.

  2024cites this paper
• Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

  2024cites this paper
• Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment

  2024cites this paper
• Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors.

  2024cites this paper
• Protein-structure-sensitive mid-infrared optoacoustic microscopy enables label-free assessment of drug therapy in myeloma cells

  2024cites this paper
• Cytotoxicity of bismuth(III) dithiocarbamate derivatives by promoting a mitochondrial-dependent apoptotic pathway and suppressing MCF-7 breast adenocarcinoma cell invasion

  2024cites this paper
• Recent Advances on Targeting Proteases for Antiviral Development

  2024cites this paper
• Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells

  2024cites this paper
• Inflammatory setting, therapeutic strategies targeting some pro-inflammatory cytokines and pathways in mitigating ischemia/reperfusion-induced hepatic injury: a comprehensive review

  2024cites this paper
• Systematic analysis of proteome turnover in an organoid model of pancreatic cancer by dSILO

  2024cites this paper
• Recent advances in the chemistry of selenophenopyrazine and selenophenopyridazine heterocycles: synthesis, reactivity, and biological activity.

  2024cites this paper
• The Proteasome Inhibitor CEP-18770 Induces Cell Death in Medulloblastoma

  2024cites this paper
• Optimal strategies of oncolytic virus-bortezomib therapy via the apoptotic, necroptotic, and oncolysis signaling network.

  2024cites this paper
• Primed for Interactions: Investigating the Primed Substrate Channel of the Proteasome for Improved Molecular Engagement

  2024cites this paper
• Peptidic boronic acid Plasmodium falciparum SUB1 inhibitors with improved selectivity over human proteasome

  2024cites this paper
• New Insights for Polyphenolic Compounds as Naturally Inspired Proteasome Inhibitors

  2023cites this paper
• Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors

  2023cites this paper
• Insights into the Tumor Microenvironment—Components, Functions and Therapeutics

  2023cites this paper
• GPDRP: a multimodal framework for drug response prediction with graph transformer

  2023cites this paper
• Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma

  2023cites this paper
• A longitudinal single-cell atlas of treatment response in pediatric AML.

  2023cites this paper
• Bortezomib-Induced Bilateral Eye Swelling and Cutaneous Adverse Reaction in a Patient with Plasma Cell Leukemia—A Case Report

  2023cites this paper
• Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond

  2023cites this paper
• High-content microscopy reveals a morphological signature of bortezomib resistance

  2023cites this paper
• Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine

  2023cites this paper
• Clinicopathological Significance of DUB3 Expression in Non-small Cell Lung Cancer and Relationship Between DUB3 Expression and LATS1 Expression

  2023cites this paper